BG
PVLA

Bellevue Group’s Palvella Therapeutics PVLA Stock Holding History

Bellevue Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7M Buy
+155,000
New +$18.8M 0.5% 45

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bellevue Group's PVLA Position: Q2 2026 in Review

Bellevue Group opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 155,000 shares worth $23.7M. The stake represents 0.5% of the portfolio and ranks #45 among its holdings.

175 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Bellevue Group held 155,000 shares of Palvella Therapeutics worth $23.7M as of Q2 2026.
  • Palvella Therapeutics was a new Bellevue Group position in Q2 2026.
  • Palvella Therapeutics made up 0.5% of Bellevue Group's portfolio in Q2 2026, its #45 holding.
  • 175 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.